Clinician POV

Clinician POV

Addressing Emerging Therapies in Early HR+/HER2− Breast Cancer

Therapy Selection in Small Cell Lung Cancer With Disease Progression After Platinum-Based Therapy

Moving Beyond Binary: Redefining HER2 Breast Cancer Classification and Treatment

Novel Androgen Receptor Pathway Inhibitors for Nonmetastatic Castration-Resistant Prostate Cancer

Selective RET Inhibitors for RET Fusion-Positive Non-Small Cell Lung Cancer

PD-1 Checkpoint Inhibitors for Deficient Mismatch Repair Recurrent or Advanced Endometrial Cancer

The Present and Future of Antibody-Drug Conjugates for Advanced HER2-Positive Breast Cancer

Management of Relapsed or Progressive Pediatric Low-Grade Glioma

Improving Outcomes in METex14 Non-Small Cell Lung Cancer: The Present and Future of Oral Therapy

Optimizing the Sequence of Therapy for Follicular Lymphoma

Development and Clinical Application of CD19xCD3 and CD20xCD3 Bispecific Antibodies

Immunotherapy With Checkpoint Inhibitors: Evolving Therapeutic Options for Esophageal Cancer

Distinguishing HER2-Negative From HER2-Low Breast Cancer

Roger Li, MD

Identifying Actionable Genetic Alterations in Metastatic Urothelial Carcinoma

Therapeutic Options for Nonmetastatic Castration-Resistant Prostate Cancer

Achieving Testosterone Suppression in Advanced Prostate Cancer

PD-L1 Inhibitors for the Treatment of Extensive-Stage Small Cell Lung Cancer

Selecting Therapy for Patients With Metastatic Pancreatic Cancer After Disease Progression

Real Progress Made in Relapsed/Refractory Multiple Myeloma, But Questions Remain

Addressing Steroid-Refractory Acute Graft-vs-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation

Decision-Making for Patients With IDH1-Mutated Relapsed or Refractory Acute Myeloid Leukemia

Targeting MET Exon 14 Skipping Mutations in Non-Small Cell Lung Cancer

Emerging Role of Selective RET Inhibitors in RET-Dependent Cancers

Therapeutic Advances for Metastatic NSCLC With EGFR Exon 20 Insertion Mutations

B-cell Maturation Antigen-Targeted Autologous CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma